Your browser doesn't support javascript.
loading
Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models.
Friese-Hamim, Manja; Ortiz Ruiz, Maria J; Bogatyrova, Olga; Keil, Marina; Rohdich, Felix; Blume, Beatrix; Leuthner, Birgitta; Czauderna, Frank; Hahn, Diane; Jabs, Julia; Jaehrling, Frank; Heinrich, Timo; Kellner, Roland; Chan, Katherine; Tong, Amy H Y; Wienke, Dirk; Moffat, Jason; Blaukat, Andree; Zenke, Frank T.
Afiliação
  • Friese-Hamim M; Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Ortiz Ruiz MJ; Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Bogatyrova O; Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Keil M; Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Rohdich F; Discovery Technologies, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Blume B; Discovery Technologies, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Leuthner B; Discovery Technologies, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Czauderna F; Research Unit Oncology, EMD Serono Research & Development Institute Inc., Billerica, Massachusetts.
  • Hahn D; Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Jabs J; Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Jaehrling F; Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Heinrich T; Discovery Technologies, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Kellner R; Discovery Technologies, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Chan K; Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
  • Tong AHY; Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
  • Wienke D; Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany.
  • Moffat J; Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
  • Blaukat A; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Zenke FT; Institute for Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
Mol Cancer Ther ; 23(2): 159-173, 2024 Feb 01.
Article em En | MEDLINE | ID: mdl-37940144
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Aminopeptidases / Neoplasias Renais Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Aminopeptidases / Neoplasias Renais Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha